European Heart Journal

Article	Citations
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	4585
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)	4449
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation	2503
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice	2040
2021 ESC/EACTS Guidelines for the management of valvular heart disease	1693
2020 ESC Guidelines for the management of adult congenital heart disease	786
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy	726
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension	714
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease	703
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus	689
COVID-19 is, in the end, an endothelial disease	633
Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era	629
European Society of Cardiology: Cardiovascular Disease Statistics 2019	621
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death	506
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the Internatio	504
Coronaviruses and the cardiovascular system: acute and long-term implications	497
Acute pulmonary embolism and COVID-19 pneumonia: a random association?	460
Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage	423
Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin	392
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy	390
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe	368
Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection	362
Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors	357
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases	349
Sex differences in heart failure	348

Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019	342
An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcircula	332
Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study	322
SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?	287
Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research	281
The ‘Digital Twin’ to enable the vision of precision cardiology	279
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study	277
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis	276
European Society of Cardiology: cardiovascular disease statistics 2021	265
Sleep patterns, genetic susceptibility, and incident cardiovascular disease: a prospective study of 385 292 UK biobank participants	246
Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance	245
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Ather	244
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force	240
The ‘Ten Commandments’ for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation	236
COVID-19-related myocarditis in a 21-year-old female patient	236
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus	234
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial	233
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement	224
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine	221
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery	218
Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts	217
C-reactive protein and clinical outcomes in patients with COVID-19	212
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis	196
Pulmonary embolism in COVID-19 patients: a French multicentre cohort study	188
COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests	171
Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes	167
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement	167
Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease	163
SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions	162
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyc	162
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study	160
Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19	156
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure o	153
Targeting cardiovascular inflammation: next steps in clinical translation	152
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation – Dual versus triple antithrombotic therapy	150
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)	150
Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome	147
Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial	142
Clinical impact of conduction disturbances in transcatheter aortic valve replacement recipients: a systematic review and meta-analysis	141
Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement	136
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)	136
Typical takotsubo syndrome triggered by SARS-CoV-2 infection	134
The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials	133
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial	129
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry	129
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy	128
Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes	126
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)	126
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction	126
The Mediterranean diet, plasma metabolome, and cardiovascular disease risk	125

Left bundle branch area pacing outcomes: the multicentre European MELOS study	124
Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists	117
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study	116
Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation	114
Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial	113
Heart failure drug treatment: the fantastic four	113
The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020	111
The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen General Population Study with 104 046 adults	109
Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials	109
Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: the HELIUS study	108
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial	107
Prevalence of statin intolerance: a meta-analysis	106
Screening for atrial fibrillation: a call for evidence	105
Clinical characteristics, diagnosis, and risk stratification of pulmonary hypertension in severe tricuspid regurgitation and implications for transcatheter tricuspid valve repair	105
European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections—endorsed by the Heart Rhythm Society (	104
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT–FFR trial	104
The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN)	103
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF	102
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials	102
Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis	100
Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme	100
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes	99
AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial	97
TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery	97
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial	97
EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic	96
Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study	95
Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank	95
Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies	93
Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis	93
Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies	92
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial	91
Genome-wide analysis identifies novel susceptibility loci for myocardial infarction	91
Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis	90
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation	89
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake	88
Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank	88
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up	88
Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk	87
Vulnerable plaques and patients: state-of-the-art	86
Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk	86
Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of ran	86
Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study	85
Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves	85
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study	85
Association between physical activity and risk of incident arrhythmias in 402 406 individuals: evidence from the UK Biobank cohort	84
Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial	83
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)	83
Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism	82
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS	81
Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry	80
Electrocardiogram screening for aortic valve stenosis using artificial intelligence	80
New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people	80
Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome	80
Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA	79
Combination lipid-lowering therapy as first-line strategy in very high-risk patients	79
2023 ESC Guidelines for the management of acute coronary syndromes	78
Comparison of in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world	78
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score	78
Sex differences and temporal trends in aortic dissection: a population-based study of incidence, treatment strategies, and outcome in Swedish patients during 15 years	77
Application of artificial intelligence to the electrocardiogram	77
Genetic predisposition to smoking in relation to 14 cardiovascular diseases	75
Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation	75
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a s	75
Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group	74
Prevention of aortic dissection and aneurysm via an ALDH2-mediated switch in vascular smooth muscle cell phenotype	74
Women who experience a myocardial infarction at a young age have worse outcomes compared with men: the Mass General Brigham YOUNG-MI registry	74
High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population	74
Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study	74
Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes	73
Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy	73
Impact of myocardial fibrosis on left ventricular remodelling, recovery, and outcome after transcatheter aortic valve implantation in different haemodynamic subtypes of severe aortic stenosis	73
Empagliflozin in acute myocardial infarction: the EMMY trial	73
Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percuta	72
Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study	71
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial	71
The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EA	71
Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations	71
Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis	71
Colchicine and the heart	70

The “ten commandments” for the 2021 ESC/EACTS Guidelines on valvular heart disease	70
Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial	70
Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry	69
Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction	69
Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR)	69
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial	68
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis	68
Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study	67
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials	67
Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombo	67
Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial	67
Return to sports after COVID-19 infection	67
Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction	67
Imaging predictors of response to cardiac resynchronization therapy: left ventricular work asymmetry by echocardiography and septal viability by cardiac magnetic resonance	66
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial	66
Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study	65
Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies	65
Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak	64
A practical risk score for early prediction of neurological outcome after out-of-hospital cardiac arrest: MIRACLE2	64
Low-grade endotoxaemia enhances artery thrombus growth via Toll-like receptor 4: implication for myocardial infarction	64
Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial	64
Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammatio	63
Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study	63
Assessment and pathophysiology of microvascular disease: recent progress and clinical implications	63
Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction	62
Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study	62
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study	62
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis	61
The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction	61
Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study	61
CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure	61
Fractional flow reserve in clinical practice: from wire-based invasive measurement to image-based computation	61
Recommendations for participation in competitive sport in adolescent and adult athletes with Congenital Heart Disease (CHD): position statement of the Sports Cardiology & Exercise Section of the E	61
Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap: results from the prospective translat	61
Twitter promotion predicts citation rates of cardiovascular articles: a preliminary analysis from the ESC Journals Randomized Study	61
Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study	61
Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease	61
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial	60
Transient complete heart block in a patient with critical COVID-19	60
COVID-19: from epidemiology to treatment	60
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy	59
Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction	59
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial	59
Acute myocardial injury, MINOCA, or myocarditis? Improving characterization of coronavirus-associated myocardial involvement	59
Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with th	59
Midlife blood pressure is associated with the severity of white matter hyperintensities: analysis of the UK Biobank cohort study	58
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk	58
Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)	58
Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences	58
Frailty and cardiovascular outcomes in the National Health and Aging Trends Study	58
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis	58
Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality	57
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology	57
Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the He	57
Feasibility of using deep learning to detect coronary artery disease based on facial photo	57
Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy	57
Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole	57
The win ratio approach for composite endpoints: practical guidance based on previous experience	57
Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19	56
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality	56
Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data	56
Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial	56
Untargeted metabolomics identifies succinate as a biomarker and therapeutic target in aortic aneurysm and dissection	56
The associations of major foods and fibre with risks of ischaemic and haemorrhagic stroke: a prospective study of 418 329 participants in the EPIC cohort across nine European countries	56
TeleCheck-AF for COVID-19	55
Does epicardial fat contribute to COVID-19 myocardial inflammation?	55
Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up	55
Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial	55
Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention	55
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis	55
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy	55
Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models	55
Metoprolol exerts a non-class effect against ischaemia–reperfusion injury by abrogating exacerbated inflammation	55
Health system, public health, and economic implications of managing COVID-19 from a cardiovascular perspective	55
Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer—a nationwide analysis	54
A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs	54
From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases	54
Genetic variability in the absorption of dietary sterols affects the risk of coronary artery disease	53
Risk of hypertension into adulthood in persons born prematurely: a national cohort study	53
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study	53
Assessing left ventricular systolic function: from ejection fraction to strain analysis	53
The ‘10 commandments’ for the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy	53
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey	53
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials	53
Clinical application of the 4th Universal Definition of Myocardial Infarction	52
Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting	52
Brugada syndrome genetics is associated with phenotype severity	52
Road traffic noise and cardiovascular disease risk factors in UK Biobank	52
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme	52
STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: a link between innate immunity and chronic inflammation caused by lifestyle-related diseases	51
Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score	51
Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial	51
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial	51
Atrial fibrillation and kidney function: a bidirectional Mendelian randomization study	51
Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial	50
The JAK–STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms	50
Stress-associated neurobiological activity associates with the risk for and timing of subsequent Takotsubo syndrome	50
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics	50
Short-coupled ventricular fibrillation represents a distinct phenotype among latent causes of unexplained cardiac arrest: a report from the CASPER registry	50
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease	49
Brugada syndrome and reduced right ventricular outflow tract conduction reserve: a final common pathway?	49
The role of genetics in cardiovascular disease: arrhythmogenic cardiomyopathy	48
The struggle towards a Universal Definition of Heart Failure—how to proceed?	48
Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis	48
Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data	48
Physical activity, cardiorespiratory fitness, and cardiovascular outcomes in individuals with atrial fibrillation: the HUNT study	48
The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study	48
Adipocyte fatty acid-binding protein exacerbates cerebral ischaemia injury by disrupting the blood–brain barrier	48
Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical	48
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR	47
Tilt testing remains a valuable asset	47
Vegetarians, fish, poultry, and meat-eaters: who has higher risk of cardiovascular disease incidence and mortality? A prospective study from UK Biobank	47
Effects of canagliflozin on human myocardial redox signalling: clinical implications	47
Acute mental stress drives vascular inflammation and promotes plaque destabilization in mouse atherosclerosis	47
Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome	47
Circulating stem cells and cardiovascular outcomes: from basic science to the clinic	47
Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary s	47
Functional tricuspid regurgitation of degenerative mitral valve disease: a crucial determinant of survival	46
Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death	46
Atrial myxomas arise from multipotent cardiac stem cells	46
Outdoor light at night and risk of coronary heart disease among older adults: a prospective cohort study	46
Sex differences in arterial hypertension	46
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial	46
Molecular imaging-guided repair after acute myocardial infarction by targeting the chemokine receptor CXCR4	45
Prevention and treatment of pulmonary congestion in patients undergoing venoarterial extracorporeal membrane oxygenation for cardiogenic shock	45
The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade	45
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	45
Silent brain infarcts and early cognitive outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis	45
The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial	45
Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers–reaching the frontiers of individual risk prediction	45
The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial	45
A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study	45
All-cause mortality and location of death in patients with established cardiovascular disease before, during, and after the COVID-19 lockdown: a Danish Nationwide Cohort Study	45
Ventricular arrhythmia burden during the coronavirus disease 2019 (COVID-19) pandemic	44
Transition to adulthood and transfer to adult care of adolescents with congenital heart disease: a global consensus statement of the ESC Association of Cardiovascular Nursing and Allied Professions (A	44
Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis	44
Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23	44
Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry	44
Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled	44
Heart healthy cities: genetics loads the gun but the environment pulls the trigger	44
Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study	44
Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?	44
Multivessel coronary thrombosis in a patient with COVID-19 pneumonia	44
Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study	44
Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis	43

Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials	43
Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure	43
Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrilla	43
Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study	43
Omics phenotyping in heart failure: the next frontier	42
Sudden cardiac death among persons with diabetes aged 1–49 years: a 10-year nationwide study of 14 294 deaths in Denmark	42
Association of the combined effects of air pollution and changes in physical activity with cardiovascular disease in young adults	42
Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA	42
Sleep arousal burden is associated with long-term all-cause and cardiovascular mortality in 8001 community-dwelling older men and women	42
The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions	42
COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions	42
Coexistence and outcome of coronary artery disease in Takotsubo syndrome	42
PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction	41
Prognostic value of stress echocardiography assessed by the ABCDE protocol	41
Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia	40
Targeting the CCL2–CCR2 axis for atheroprotection	40
Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: impact on healing	40
Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction	40
Adipocytes promote interleukin-18 binding to its receptors during abdominal aortic aneurysm formation in mice	40
Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction	40
Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications	40
Macrophage NFATc3 prevents foam cell formation and atherosclerosis: evidence and mechanisms	39
2023 ESC Guidelines for the management of cardiomyopathies	39
Current use and safety of novel oral anticoagulants in adults with congenital heart disease: results of a nationwide analysis including more than 44 000 patients	39
Aetiology and outcomes of severe right ventricular dysfunction	39
Reduction of environmental pollutants for prevention of cardiovascular disease: it’s time to act	39
Critical appraisal of artificial intelligence-based prediction models for cardiovascular disease	39
Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy	39
Sodium intake, life expectancy, and all-cause mortality	39
Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective	38
Artificial intelligence in the diagnosis and management of arrhythmias	38
Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy	38
CAPACITY-COVID: a European Registry to determine the role of cardiovascular disease in the COVID-19 pandemic	38
Impact of cardiovascular risk factors and genetics on 10-year absolute risk of dementia: risk charts for targeted prevention	38
Silent brain infarcts impact on cognitive function in atrial fibrillation	38
Right ventricle assessment in patients with pulmonary embolism at low risk for death based on clinical models: an individual patient data meta-analysis	37
Targeted proteomics improves cardiovascular risk prediction in secondary prevention	37
Smoking cessation, but not reduction, reduces cardiovascular disease incidence	37
The dawn of a new era of targeted lipid-lowering therapies	37
When genetic burden reaches threshold	37
Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study	37
Determinants of outcomes following surgery for type A acute aortic dissection: the UK National Adult Cardiac Surgical Audit	37
Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney	37
Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction:	37
Impact of sex on the management and outcome of aortic stenosis patients	37
Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score	37
Exclusion of pregnant and lactating women from COVID-19 vaccine trials: a missed opportunity	36
An autoantibody profile detects Brugada syndrome and identifies abnormally expressed myocardial proteins	36
Extracellular vesicles from immortalized cardiosphere-derived cells attenuate arrhythmogenic cardiomyopathy in desmoglein-2 mutant mice	36
A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction	36
Integrated management of atrial fibrillation in primary care: results of the ALL-IN cluster randomized trial	36
Myocardial injury in severe COVID-19 infection	35
Physical activity and fitness in the community: the Framingham Heart Study	35
COVID-19 experience in Bergamo, Italy	35
Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study	35
Twitter-based learning for continuing medical education?	35
Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study	35
Mapping interventional cardiology in Europe: the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Atlas Project	35
Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: implications for understanding the effects of current and future treatments for heart failure	35
Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction	35
SGLT2 inhibitors: the statins of the 21st century	35
Supracardiac atherosclerosis in embolic stroke of undetermined source: the underestimated source	34
High-density lipoprotein revisited: biological functions and clinical relevance	34
Implementing the new European Regulations on medical devices—clinical responsibilities for evidence-based practice: a report from the Regulatory Affairs Committee of the European Society of Cardiology	34
Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study	34
A leucopoietic-arterial axis underlying the link between ambient air pollution and cardiovascular disease in humans	34
Nomenclature for kidney function and disease—executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference	34
Does night-time aircraft noise trigger mortality? A case-crossover study on 24 886 cardiovascular deaths	34
Coronavirus disease 2019 in adults with congenital heart disease: a position paper from the ESC working group of adult congenital heart disease, and the International Society for Adult Congenital Hear	33
Accelerated and personalized therapy for heart failure with reduced ejection fraction	33
Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006–2015	33
Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology	33
Endocardial/endothelial angiocrines regulate cardiomyocyte development and maturation and induce features of ventricular non-compaction	33
Timing of intervention in asymptomatic patients with valvular heart disease	33
Fulminant COVID-19-related myocarditis in an infant	33
A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial	33
Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study	33
Iron deficiency and cardiovascular disease	33
ESC Core Curriculum for the Cardiologist	33
Accelerometer-derived physical activity and risk of atrial fibrillation	33
Corrigendum to: 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (	32
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized cl	32
Modifiable risk factors associated with cardiovascular disease and mortality in China: a PURE substudy	32
Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation	32
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial	32
Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study	32
Long-term cardiovascular disease mortality among 160 834 5-year survivors of adolescent and young adult cancer: an American population-based cohort study	32
2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease	32
Ultra-processed food intake and all-cause and cause-specific mortality in individuals with cardiovascular disease: the Moli-sani Study	32
Cholesterol crystals and atherosclerosis	32
An automated computational image analysis pipeline for histological grading of cardiac allograft rejection	32
Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm	32
Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study	32
Peripartum cardiomyopathy: from genetics to management	32
Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification	32
A systematic review and meta-analysis of beta-blockers and renin–angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast	31
Automated external defibrillators delivered by drones to patients with suspected out-of-hospital cardiac arrest	31
Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction	31
Simple electrocardiographic measures improve sudden arrhythmic death prediction in coronary disease	31
Lack of specialist care is associated with increased morbidity and mortality in adult congenital heart disease: a population-based study	31
Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies	31
Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia	31
Statin associated lower cancer risk and related mortality in patients with heart failure	31
Precision Medicine and cardiac channelopathies: when dreams meet reality	31
Importance of genetic testing in unexplained cardiac arrest	31
Stress-associated neurobiological activity is linked with acute plaque instability via enhanced macrophage activity: a prospective serial 18F-FDG-PET/CT imaging assessment	30
Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies	30
Trends in survival after cardiac arrest: a Swedish nationwide study over 30 years	30
Does SARS-CoV-2 cause viral myocarditis in COVID-19 patients?	30
Functionally validated SCN5A variants allow interpretation of pathogenicity and prediction of lethal events in Brugada syndrome	30
Coronary stent CD31-mimetic coating favours endothelialization and reduces local inflammation and neointimal development in vivo	30
COVID-19 pandemic: a sentiment analysis	30
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis	30
Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice	30
The PROFID project	29
Screening in children for familial hypercholesterolaemia: start now	29
Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial	29
The haemochromatosis gene Hfe and Kupffer cells control LDL cholesterol homeostasis and impact on atherosclerosis development	29
Risk factors for type 1 and type 2 myocardial infarction	29
Temporal changes in total and hippocampal brain volume and cognitive function in patients with chronic heart failure—the COGNITION.MATTERS-HF cohort study	29
Restrictive cardiomyopathy: definition and diagnosis	29
The collateral damage of COVID-19 to cardiovascular services: a meta-analysis	29
Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography a	29
Vigorous physical activity, incident heart disease, and cancer: how little is enough?	29
Lipoproteins in chronic kidney disease: from bench to bedside	29
Interpretation and actionability of genetic variants in cardiomyopathies: a position statement from the European Society of Cardiology Council on cardiovascular genomics	29
Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator	29
Chronic venous insufficiency, cardiovascular disease, and mortality: a population study	29
A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity	29
Myocardial hypoxic stress mediates functional cardiac extracellular vesicle release	28
Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment	28
Importance of sex and gender in ischaemic stroke and carotid atherosclerotic disease	28
Cardiovascular disease, mortality, and their associations with modifiable risk factors in a multi-national South Asia cohort: a PURE substudy	28
The association between coronary graft patency and clinical status in patients with coronary artery disease	28
Contribution of income and job strain to the association between education and cardiovascular disease in 1.6 million Danish employees	28
Bone marrow activation in response to metabolic syndrome and early atherosclerosis	28
Immediate post-procedural functional assessment of percutaneous coronary intervention: current evidence and future directions	28
Trends in aortic valve replacement for aortic stenosis: a French nationwide study	28
Alarmin-activated B cells accelerate murine atherosclerosis after myocardial infarction via plasma cell-immunoglobulin-dependent mechanisms	28
Genome-wide association study identifies 18 novel loci associated with left atrial volume and function	27
The ‘Ten Commandments’ of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	27
What we (don’t) know about myocardial injury after COVID-19	27
Patient-tailored antithrombotic therapy following percutaneous coronary intervention	27
Validation of the European Society of Cardiology pre-test probability model for obstructive coronary artery disease	27
The 2019 ESC Guidelines for the Management of Patients with Supraventricular Tachycardia	27
Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation?	27
Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke	27
Chronic infarct size after spontaneous coronary artery dissection: implications for pathophysiology and clinical management	27
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial	27
A call to action for new global approaches to cardiovascular disease drug solutions	27
Management of refractory angina: an update	27
Pregnancy loss and risk of cardiovascular disease: the Nurses’ Health Study II	27
Impact of COVID-19 pandemic restrictions on ST-elevation myocardial infarction: a cardiac magnetic resonance imaging study	27
Management of non-culprit coronary plaques in patients with acute coronary syndrome	27
Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction	27
Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout	26
Corrigendum to: European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis; an	26
Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes	26
Right ventricular dilatation in arrhythmogenic right ventricular cardiomyopathy: need for a revision of the 2010 International Task Force criteria	26
Hypertensive disorders of pregnancy and onset of chronic hypertension in France: the nationwide CONCEPTION study	26
Apple Watch detecting coronary ischaemia during chest pain episodes or an apple a day may keep myocardial infarction away	26
Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study	26
Hypertension in children and adolescents	26
Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom	26
Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis	26
Dapagliflozin for heart failure according to body mass index: the DELIVER trial	26
SARS-CoV-2 receptor ACE2 expression in the human heart: cause of a post-pandemic wave of heart failure?	26
Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivessel disease: a randomized trial	26
Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality	26
Impact of cholesterol on proinflammatory monocyte production by the bone marrow	26
Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF	26
Low ambient temperature and temperature drop between neighbouring days and acute aortic dissection: a case-crossover study	26
Deep learning analysis of electrocardiogram for risk prediction of drug-induced arrhythmias and diagnosis of long QT syndrome	25
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled	25
Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients	25
Purkinje network and myocardial substrate at the onset of human ventricular fibrillation: implications for catheter ablation	25
Pregnancy-associated arterial dissections: a nationwide cohort study	25
Obesity and cardiovascular health: the size of the problem	25
Maternal and neonatal complications in women with congenital heart disease: a nationwide analysis	25
Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventio	25
Understanding the genetics of adult-onset dilated cardiomyopathy: what a clinician needs to know	25
Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis o	25
Genetic insight into sick sinus syndrome	25
Risk stratification of patients with cardiac sarcoidosis: the ILLUMINATE-CS registry	25
Prevalence, incidence, and outcomes across cardiovascular diseases in homeless individuals using national linked electronic health records	25
One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study	25
Discriminatory cardiac arrest care? Patients with low socioeconomic status receive delayed cardiopulmonary resuscitation and are less likely to survive an in-hospital cardiac arrest	24
Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations	24
Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial	24
Insomnia symptoms and incident heart failure: a population-based cohort study	24
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54	24
Immune cells in cardiac homeostasis and disease: emerging insights from novel technologies	24
2023 ESC Guidelines for the management of endocarditis	24
Sex associations and computed tomography coronary angiography-guided management in patients with stable chest pain	24
Sudden cardiac death in congenital heart disease	24
Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial	24
Cardiac magnetic resonance identifies raised left ventricular filling pressure: prognostic implications	24
Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trials	24
Alert system-supported lay defibrillation and basic life-support for cardiac arrest at home	24
Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy	24